CollPlant Gets New Patent for Dermal Filler
Ticker: CLGN · Form: 6-K · Filed: Feb 12, 2025 · CIK: 1631487
Sentiment: bullish
Topics: patent, biotechnology, dermal filler
TL;DR
CollPlant just snagged another patent for its dermal filler tech, boosting its IP.
AI Summary
CollPlant Biotechnologies Ltd. announced on February 12, 2025, that it has been granted an additional patent for its photocurable dermal filler program. This patent, related to the use of its proprietary plant-derived recombinant human collagen (rhCollagen) in combination with specific cross-linking agents, further strengthens the company's intellectual property portfolio for this innovative product.
Why It Matters
This patent strengthens CollPlant's intellectual property in the lucrative dermal filler market, potentially enhancing its competitive position and future commercialization efforts.
Risk Assessment
Risk Level: low — The filing is an informational report about a patent grant, which is generally a positive development with low immediate risk.
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- February 2025 (date) — Reporting period
- 001-38370 (other) — Commission File Number
FAQ
What is the subject of the new patent granted to CollPlant Biotechnologies Ltd.?
The new patent is for CollPlant's photocurable dermal filler program, specifically related to the use of its proprietary plant-derived recombinant human collagen (rhCollagen) in combination with specific cross-linking agents.
When was this patent grant announced?
The announcement was made in a Form 6-K filing on February 12, 2025.
What is CollPlant's proprietary technology mentioned in the filing?
CollPlant's proprietary technology involves plant-derived recombinant human collagen (rhCollagen).
What type of product does the patent relate to?
The patent relates to a photocurable dermal filler.
What is the Commission File Number for CollPlant Biotechnologies Ltd.?
The Commission File Number is 001-38370.
Filing Stats: 346 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2025-02-12 06:23:34
Filing Documents
- ea0230747-6k_collplant.htm (6-K) — 12KB
- ea023074701ex99-1_collplant.htm (EX-99.1) — 18KB
- ea023074701ex99-2_collplant.htm (EX-99.2) — 37KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- ex99-2_001.jpg (GRAPHIC) — 683KB
- ex99-2_002.jpg (GRAPHIC) — 1693KB
- ex99-2_003.jpg (GRAPHIC) — 748KB
- ex99-2_004.jpg (GRAPHIC) — 768KB
- ex99-2_005.jpg (GRAPHIC) — 505KB
- ex99-2_006.jpg (GRAPHIC) — 502KB
- ex99-2_007.jpg (GRAPHIC) — 730KB
- ex99-2_008.jpg (GRAPHIC) — 500KB
- ex99-2_009.jpg (GRAPHIC) — 539KB
- ex99-2_010.jpg (GRAPHIC) — 439KB
- ex99-2_011.jpg (GRAPHIC) — 434KB
- ex99-2_012.jpg (GRAPHIC) — 495KB
- ex99-2_013.jpg (GRAPHIC) — 967KB
- ex99-2_014.jpg (GRAPHIC) — 616KB
- ex99-2_015.jpg (GRAPHIC) — 590KB
- ex99-2_016.jpg (GRAPHIC) — 754KB
- ex99-2_017.jpg (GRAPHIC) — 667KB
- ex99-2_018.jpg (GRAPHIC) — 657KB
- ex99-2_019.jpg (GRAPHIC) — 584KB
- ex99-2_020.jpg (GRAPHIC) — 565KB
- ex99-2_021.jpg (GRAPHIC) — 410KB
- ex99-2_022.jpg (GRAPHIC) — 527KB
- ex99-2_023.jpg (GRAPHIC) — 509KB
- ex99-2_024.jpg (GRAPHIC) — 639KB
- ex99-2_025.jpg (GRAPHIC) — 471KB
- ex99-2_026.jpg (GRAPHIC) — 636KB
- ex99-2_027.jpg (GRAPHIC) — 449KB
- ex99-2_028.jpg (GRAPHIC) — 701KB
- ex99-2_029.jpg (GRAPHIC) — 462KB
- ex99-2_030.jpg (GRAPHIC) — 612KB
- ex99-2_031.jpg (GRAPHIC) — 512KB
- ex99-2_032.jpg (GRAPHIC) — 640KB
- ex99-2_033.jpg (GRAPHIC) — 693KB
- ex99-2_034.jpg (GRAPHIC) — 592KB
- ex99-2_035.jpg (GRAPHIC) — 1349KB
- 0001213900-25-012476.txt ( ) — 31258KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: February 12, 2025 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2